Format

Send to

Choose Destination
Oncotarget. 2017 May 6;8(43):75350-75360. doi: 10.18632/oncotarget.17642. eCollection 2017 Sep 26.

Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies.

Author information

1
Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
2
College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
3
Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
4
Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China.
5
Medical Record Statistics Office, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.
6
College of Professional Study, Northeastern University, Boston, Massachusetts, USA.

Abstract

Previous studies showed that microRNA-214 (miR-214) may act as a prognostic biomarker of cancer. However, the available evidence is controversial. This study summarizes evidence and evaluates the prognostic role of miR-214 in various cancers. We carried out a systematic literature review and assessed the quality of included studies based on Oxford Centre for Evidence-based Medicine Criteria and Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for overall survival (OS) and disease free survival/progressive free survival/recurrence free survival (DFS/PFS/RFS) were calculated to measure the effective value of miR-214 expression on prognosis. Thirteen studies were included in pooled analysis. We found that miR-214 was significantly correlated with OS (HR=2.21, 95%CI: 1.33-3.68, P=0.00), no significant difference was found with DFS/PFS/RFS (HR=1.73, 95%CI: 0.78-3.83, P=0.18) in various carcinomas. In subgroup analysis, higher expression of miR-214 was significantly associated with poor OS in Asians (HR=2.27, 95%CI: 1.09-4.73, P=0.00) and Caucasians (HR=2.04, 95%CI: 1.47-3.30, P=0.00). On the contrary, high miR-214 expression significantly predicted favorable DFS/PFS/RFS (HR=0.50, 95%CI: 0.31-0.82, P=0.00) in hepatocellular carcinoma (HCC) group. Our data indicates that high miR-214 could be a promising biomarker for prognosis prediction of cancer. However, further clinical studies are needed for the current insufficient relevant data.

KEYWORDS:

cancer; miR-214; prognosis; systematic evaluation

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflict of interests.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center